GSK: A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC):
Pfizer C3441021 - TALAPRO: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYOF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATICCASTRATION-RESISTANT PROSTATE CANCER
"ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer"
Pfizer: (EZH2): 235999: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITHRELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULARLYMPHOMA (FL):
For more information about Beverly Hills Cancer Center's comprehensive clinical research programs and trials currently available to patients, please contact us at (310) 432-8932 or click here to send in an inquiry.
To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or Click the link below to access our Online Appointment Request
Book An Appointment© Beverly Hills Cancer Center. All Rights Reserved. Web Design & Internet Marketing by Studio III
